Dispensing Biotechnology Products: Handling, Professional Education, and Product Information

  • Robert D. SindelarEmail author


With more then three decades of pharmacy practice experience involving biotech-derived drugs, the impact of biologics in community and institution settings for patient care and disease management has never been larger. Preparation, dispensing, and patient education regarding appropriate use of pharmaceuticals are primarily the responsibility of the pharmacist. Traditionally, parenteral products have been available in ready-to-use containers or required appropriate dilution with sterile water or saline prior to use with no other special handling requirements. Hospital pharmacists, in particular, have prepared and dispensed parenteral products for individual patients for many years. While many pharmacists are skilled in handling parenteral products, biotechnology products present additional challenges since they are predominately proteins subject to physical and chemical denaturation and thus require special handling techniques. These challenges will be explained in greater detail in this chapter. Practice issues with biotechnology products may be handled in slightly different ways depending on laws and pharmacy practice standards in each country. This chapter is written primarily from the view of practice in the United States since that is the primary experience of the original chapter authors.


Medicare benefit policy manual U.S. Centers for Medicare & Medicaid Services (CMS) J-Code Managed care organizations Specialty pharmacies Pharmacy benefits management Storage Travel requirements Filtration Flushing solutions Reimbursement 


  1. AbbVie Inc. (2018) Humira® information. Accessed at: Accessed 25 May 2018
  2. AHFS (2018) American hospital formulary service drug information. American Society of Health-System Pharmacists. Accessed at: Accessed 25 May 2018
  3. American Society of Health-System Pharmacists (2017) ASHP guidelines on compounding sterile preparations. Accessed at: Accessed 25 May 2018
  4. Amgen Inc. (2018a) Epogen® information. Accessed at: Accessed 21 May 2018
  5. Amgen Inc. (2018b) Neupogen® information. Accessed at: Accessed 21 May 2018
  6. Amgen Inc. (2018c) Prolia® information. Accessed at: Accessed 25 May 2018
  7. Amgen Inc. (2018d) Xgeva® information. Accessed at: Accessed 25 May 2018
  8. Artemetrix (2017) 2017 State of specialty management - specialty drug trend report. Accessed at: Accessed 25 May 2018
  9. Bagwell A, Kelley T, Carver A, Lee JB, Newman B (2017) Advancing patient care through specialty pharmacy services in an academic health system. J. Manag Care Spec Pharm 23:815–820PubMedGoogle Scholar
  10. Banga AK, Reddy IK (1994) Biotechnology drugs: pharmaceutical issues. Pharm Times 60:68–76Google Scholar
  11. Bayer HealthCare (2018) Betaseron® full prescribing information. Accessed 21 May 2018
  12. Department of Health and Human Services (2018) CMS manual system, Pub 100–02 Medicare Benefit Policy, Chapter 15. Accessed at: Accessed 08 May 2018
  13. Drug Channels (2018) The top 15 specialty pharmacies of 2017: PBMs and payers still dominate. Accessed at: Accessed 25 May 2018
  14. Finn TE, Nunez AC, Sunde M, Easterbrook-Smith SB (2012) Serum albumin prevents protein aggregation and amyloid formation and retains chaperone-like activity in the presence of physiological ligands. J Biol Chem 28:21530–21540CrossRefGoogle Scholar
  15. Genentech (2018a) Pulmozyme® information. Accessed at: Accessed 25 May 2018
  16. Genentech (2018b) Activase® information. Accessed at: Accessed 21 May 2018
  17. HDA Research Foundation (2018) Specialty Pharmaceutical Distribution Facts, Figures and Trends. Accessed at: . Accessed 22 May 2018
  18. King Guide (2018) King guide to parenteral admixture. King Guide Publications, Inc. Accessed at: Accessed 25 May 2018
  19. Managed Care (2014) Provider-administered drugs move to specialty pharmacy benefit. Manag Care 23:49Google Scholar
  20. McDermott DF, Regan MM, Clark JI et al (2005) Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23(1):133–141CrossRefGoogle Scholar
  21. National Association of Specialty Pharmacy (2018). Accessed at: Accessed 25 May 2018
  22. Prometheus Therapeutics & Diagnostics (2018) Proleukin® information. Accessed at: Accessed 21 May 2018
  23. Rayfield WJ, Kandula S, Khan H, Tugcu N (2017) Impact of freeze/thaw process on drug substance storage of therapeutics. J Pharm Sci 106:1944–1951CrossRefGoogle Scholar
  24. Roche Laboratories (2018) Summary of product characteristics. Accessed at: Accessed 24 May 2018
  25. RxList (2018) Intron® information. Accessed at: Accessed 21 May 2018
  26. Sanofi-Aventis (2018) Leukine® information. Accessed at: Accessed 21 May 2018

Suggested Reading

  1. See Tables  10.1,  10.2, and  10.4 for suggested readings

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Faculty of Pharmaceutical Sciences and The Centre for Health Evaluation & Outcomes Sciences (CHEOS)The University of British Columbia (UBC)VancouverCanada
  2. 2.Global Drug Commercialization Centre (GDCC)-China and GDCC-worldwideChengduChina

Personalised recommendations